Inactive Instrument

Highlights Biocept Inc Nasdaq

Equities

US09072V2043

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer	23-09-21	CI
Biocept Signs Non-Exclusive Licensing Agreement With Plus Therapeutics on CNSide Tumor Cell Platform	23-09-08	MT
Plus Therapeutics, Inc. Enters into License Agreement with Biocept for Cerebrospinal Fluid Tumor Cell Enumeration Assay	23-09-08	CI
Earnings Flash (BIOC) BIOCEPT Reports Q2 Revenue $589,000	23-08-14	MT
Biocept, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Biocept, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Biocept, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Biocept, Inc. Announces Enrollment of the First Patient in the FORESEE Clinical Trial with the Proprietary Cerebrospinal Fluid Assay	23-03-24	CI
Biocept Q3 Loss Widens, Revenue Drops	22-11-21	MT
Biocept, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-21	CI
Earnings Flash (BIOC) BIOCEPT Posts Q3 Revenue $5.6M	22-11-21	MT
Biocept Announces Participation in Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System	22-11-16	CI
Biocept, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-11-10	CI
Earnings Flash (BIOC) BIOCEPT Reports Q2 Revenue $10.6M	22-11-10	MT
Biocept, Inc. Expands Commercial Offering of Cnside(Tm) Assay to Most Cancers That Metastasize to the Central Nervous System	22-10-17	CI
Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial	22-06-22	CI
Biocept Swings to Q1 Loss, Revenue Rises	22-05-23	MT
Earnings Flash (BIOC) BIOCEPT Posts Q1 Revenue $19.9M	22-05-23	MT
Biocept, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-23	CI
Earnings Flash (BIOC) BIOCEPT Reports Q4 Revenue $14M, vs. Street Est of $11.1M	22-04-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Biocept Inc Nasdaq

Equities

US09072V2043

Highlights

Filters